The influence of oral contraceptives on lamotrigine clearance in patients on lamotrigine in combination with valproic acid, carbamazepine or oxcarbazepine as compared to patients on lamotrigine only.

The influence of oral contraceptives on lamotrigine clearance in patients on lamotrigine in combination with valproic acid, carbamazepine or oxcarbazepine as compared to patients on lamotrigine only. - ltg/oc in combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32536

Enrollment

Registered

2009-10-22

Start date

2010-02-09

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: women in the age of 18-40 years that use OC in a stable dose as well as a stable dose of 1)LTG and VPA, 2)LTG and CBZ, 3)LTG and OCB.

Exclusion criteria

Exclusion criteria: Use of steroid hormones (other than OC) as well as pregnancy or the intention to conceive, current breastfeeding or having delivered in the nine months prior to the study. Patients with abnormal liver and/or renal function or with known gynaecological or psychiatric co morbidity will be excluded.

Design outcomes

Secondary

Measure	Time frame
seizures and side effects will be secundary parameters.	—

Primary

Measure	Time frame
LTG serum levels as well as serum levels of VPA, or CBZ or OCB during the cycles will be primary study parameters.	—

Countries

Netherlands

Outcome results